CN1085080C - Medicine for treating and preventing saturnism and its preparing process - Google Patents
Medicine for treating and preventing saturnism and its preparing process Download PDFInfo
- Publication number
- CN1085080C CN1085080C CN00106079A CN00106079A CN1085080C CN 1085080 C CN1085080 C CN 1085080C CN 00106079 A CN00106079 A CN 00106079A CN 00106079 A CN00106079 A CN 00106079A CN 1085080 C CN1085080 C CN 1085080C
- Authority
- CN
- China
- Prior art keywords
- medicine
- component
- solution
- zinc
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The present invention relates to a medicine for treating and preventing plumbism and a preparation method thereof. The medicine of the present invention comprises alginate (A), chitin derivatives (B), soluble calcium salt (C) and soluble zinc salt (D). The preparation method of the medicine comprises: a gelation reaction is carried out among the (A), the (B) and the (C) proportionally mixed to generate a difficultly soluble substance which is washed with water and dried; the difficultly soluble substance is dewatered, dried and pulverized after being soaked with the (D). Active groups, such as carboxyl groups, alcoholic hydroxyl groups, amino groups, etc., contained in the medicine of the present invention can remove the toxic hazard of plumbum, mercury, cadmium, etc.; calcium and zinc which are contained in the medicine performs the protective action on the plumbism.
Description
The present invention relates to a kind of saturnine medicine for the treatment of and prevent.Specifically the present invention relates to a kind of is the composition of medicine of primary raw material preparation with marine organisms, the invention still further relates to the preparation method of this medicine.
Lead is a kind of serious neurotoxic substance and environmental poisonous substance of endangering, and along with a large amount of uses of leaded material, lead contamination problem, particularly environment lead more and more are subjected to extensive concern to child's influence.Plumbous infringement to human body, mainly be to enter after the human body by respiratory tract, digestive tract and skin, accumulate at each organ and to cause, its performance is influence erythrocytic function and the life-span, cause the heart autonomic nervous dysfunction, cause damage, damage renal tubular function etc. forming the synthetic and cranial nerve cell of the new albumen that plays a crucial role in the longterm memory.Plumbous influence to the child especially receives publicity, because it is often contact or edible thing of child that paint, study article, greasepaint are coated with leaded many article such as skin, colored toy and puffed rice, because of the dry paint chip that strips off, lead tolerance can reach 5-70%, the lacquer bits that nail cover is big can be more than the leaded 50mg, and children's eats by mistake once just can cause poisoning.In air, near ground, lead content is high more because of more, and the lead that the child bears exposes external dose, and also the adult is high.On the other hand, because child's kidney can't can be drained lead timely and effectively as the adult, plumbous the intravital retention of the child time than being grown up about 5 times of length, and that child's the intestines and stomach is grown up to the absorbance of lead is high 5 times, and it is higher tens times than the adult that this shows that the child is subjected to plumbous harm.Data shows that also developing country's children ' s lead poisoning phenomenon is very general, and developed countries such as the U.S. also are considered as lead poisoning No.1 child's environmental health problems, even legislation forces to carry out the blood lead inspection.Because physiological reason, the child is responsive especially to the neurotoxicity of lead, jeopardizes intelligence development.51.6% lead levels surpasses 10ug/dL in China city, and promptly half child of city is subjected to the lead poisoning threat, and the every increase of Pb-B 10ug/dL, IQ just reduces the 1-3 branch.As seen, plumbous harm to the child is very serious.
At present, treating saturnine method clinically mainly is to drive lead with chelating agent such as calcium disodium chelate, but chelating agent drives plumbous owing to do not have specificity, in the time of Plumbum removing, trace element (as calcium, zinc etc.) essential in the body also loses in a large number, and health is had very big side effect, and takes also inconvenient.Therefore, general clinically only just use after the lead poisoning symptom occurs.Chinese patent CN 1079387A discloses a kind of medicine and method for making thereof for the treatment of uremia, heavy metal poisoning disease.The medicine of this invention can be treated the heavy metal poisoning disease that comprises lead poisoning effectively, and this medicine can remedy the calcium that runs off because of lead poisoning effectively; But lead poisoning can also cause high urine zinc simultaneously, thereby causes zinc to run off in a large number, and this invention medicine is powerless to this.Known, zinc is one of important trace element essential in the body, participates in the activity of plurality of enzymes.On the one hand,, cause zinc deficiency in the body, reduced the activity of various enzymes, General Symptoms such as cause that appetite descends, loses weight because the early stage zinc of contamination (refer to lead poisoning, down with) is discharged with urine is a large amount of; On the other hand, because lead poisoning can damage protein synthesis in the longterm memory process, and the damage of the Hippocampus synapse that zinc causes lead has important protective effect, and therefore, the shortage of zinc can further increase saturnine probability and harm.Saturnine morning, mid-term, symptom was not obvious, in case plumbously accumulate then be difficult to fully discharge, the severe lead poisoning also can cause the irreversible infringement of nervus centralis.And the medicine of this patent can only be used for saturnine anaphase, and lead poisoning is not had prevention and inhibitory action.Therefore, seek a kind of can before the lead poisoning symptom occur, effectively prevent and treat lead poisoning and medicine that can zinc supplement significant.
One of purpose of the present invention be at prior art can not be in the saturnine while zinc supplement of treatment, can not play the defective of preventive effect to lead poisoning, a kind of saturnine medicine that prevents and treat is provided.
Another object of the present invention provides a kind of method for preparing prevention and treatment lead poisoning medicine.
The invention provides a kind of saturnine medicine for the treatment of and prevent.
Described medicine can comprise following component:
A, concentration expressed in percentage by weight is the na alginate soln of 0.5-6%;
B, concentration expressed in percentage by weight is carboxymethyl chitin sodium salt or the carboxymethyl chitosan sodium salt of 1-10%;
C, concentration expressed in percentage by weight is the soluble calcium salt of 0.5-30%;
D, zinc ion concentration are the soluble zinc salt of 200-850 mg/litre.
This medicine can be made as follows:
(1) A component and B component are pressed (10～1): 1 weight ratio fully stirs, mix homogeneously;
(2) in A, B component mixed glue solution, add the C component, in solution, carry out gelling reaction, become clear solution up to reactant liquor, till gel is separated out;
(3) take out gel, through washing, drying is made powder;
(4) will be 1 with the D components by weight: the powder in the above-mentioned steps of (1～50) (3) be soaked in the D component, and jolting 0.5-3 hour, centrifuge dehydration, 0-100 ℃ is dry down, pulverizes and makes medicine of the present invention.
Because A component and B component all are extracts, when carrying out gelling reaction, only respond and finally finish with the C component, reactant liquor could bleach.For the mixed glue solution of being made up of a certain amount of A component and B component, the consumption of C component also is certain during the reactant liquor bleach.
Wherein, described A component alginic acid can be the block copolymer of D-mannuronic acid and L-guluronic acid, the ratio of the two can be (1～2): 1, and the contained L-guluronic acid of alginic acid that wherein extracts from the preferred decomposite leaf Alga Sgrgassi Enerves of the present invention is higher, good drug efficacy.The preferred 1-3% of the concentration expressed in percentage by weight of A component.Alginic acid in the described A component is preferably extracted by Sargassum or Thallus Laminariae (Thallus Eckloniae): with concentration is the sodium carbonate liquor of 0.6-1% (weight), extracts 2-4 hour under 30-60 ℃ of temperature, removes the rhizome residue, makes solution of sodium alginate.Extract the preferred concentration 1% of the used sodium carbonate liquor of alginic acid, 60 ℃ of preferred temperature, the particularly preferred concentration of the solution of sodium alginate of preparation are 1-2% (weight).
Described B component can be selected from carboxymethyl chitin sodium salt or carboxymethyl chitosan sodium salt; The concentration expressed in percentage by weight of B component can be 1-10%, preferred 2-5%.Described B component (chitin derivativ) is preferably removed crustacean inorganic salt, protein impurities by shell-fish (shrimp, Carapax Eriocheir sinensis) with diluted acid, diluted alkaline, is prepared from then.For example: with 1 mole hydrochloride solution room temperature decalcification 12 hours, 100 ℃ of following deproteinization of 10% sodium hydroxide solution 4 hours, 1 mole hydrochloride room temperature was handled 2 hours again, made chitin; Chitin usefulness 40-50%NaOH solution makes chitosan 100 ℃ of following deacetylated processing 4 hours; Chitin or chitosan reacted 2 hours down at 20-65 ℃ with 1: 1.2 chloroacetic acid solution, regulated pH value, used methanol wash, and 60 ℃ of oven dry down make carboxymethyl chitin sodium salt or carboxymethyl chitosan sodium salt.The used NaOH solution preferred concentration of preparation B component is 40-45%, the preferable ratio of monoxone 1: 1.2,108 ℃ of preferred temperature.
Described C component can be selected from a kind of in calcium acetate, calcium chloride, calcium lactate, the vinegar system Concha Ostreae (calcined) solution, preferably uses vinegar system Concha Ostreae (calcined) solution, and preferred calcic concentration expressed in percentage by weight is 1-2%.The preferred 0.5-10% of the concentration expressed in percentage by weight of C component.Described C component is preferably made through acid is molten by Concha Ostreae (calcined).For example, can be at first with 6-18 degree vinegar extraction 1-3 hour, filter and remove residue, make calcium acetate solution, or directly with dilute hydrochloric acid, acetate dissolution preparation.
Describedly be used to soak that the D component of product can be soluble zinc salts such as zinc chloride, zinc nitrate, zinc acetate, zinc sulfate in the middle of the powdery, zinc acetate preferably, its contain zinc concentration with the 400-850 mg/litre for well.The baking temperature of middle product and final products is 0-100 ℃, preferred 60-80 ℃.
The preferred medicine of the present invention is to be primary raw material with marine organisms Sargassum, Thallus Laminariae (Thallus Eckloniae), shell-fish, Concha Ostreae (calcined), extract its effective site---alginic acid, chitin and divalent ions such as derivant, calcium thereof, utilize the active group in its molecular structure, quantitatively the calcium type preparation of making in conjunction with zinc.The preparation method of medicine of the present invention can may further comprise the steps:
(1) A component and B component are pressed (10～1): 1 weight ratio fully stirs, mix homogeneously;
(2) add the C component slowly in A, B component mixed glue solution, slowly stir, carry out gelling reaction in solution, become clear solution up to glue, pH reaches 7, till gel is separated out;
(3) take out gel, through the washing desalination, dehydration, drying is made Powdered middle product;
(4) will be 1 with the D components by weight: the powder that the above-mentioned steps of (1～50) (3) makes be soaked in the D component, and jolting 0.5-3 hour, centrifuge dehydration, drying is made medicine of the present invention.
Baking temperature in above-mentioned steps (3) and (4) can be 0-100 ℃, preferred 60-80 ℃.
Certainly, it is raw material that medicine of the present invention also can adopt A, B, C, D four components, with other conventional method preparations.
Except that A, B, C, D four components, medicine of the present invention can also add an amount of excipient.Described excipient is selected from one or more of sodium carboxymethyl cellulose, starch, pectin, Radix Acaciae senegalis, lactose, sucrose, stearic acid, hard magnesium or mannitol etc., makes dosage forms such as pill, tablet, powder, capsule, serosity for oral.
The performance and the drug effect of medicine of the present invention are described in further detail below in conjunction with accompanying drawing and experimental data.
Accompanying drawing 1 is the infrared spectrogram of medicine of the present invention.
Instrument is: Perkin Elmer Spectrum BX FT-IR Sytem
Method for making sample is: the KBr compressing tablet
In the infrared spectrum:
3800-2500cm
-1Wide absworption peak derives from alginic acid and is the carboxymethyl crusta of raw material preparation by chitin The stretching vibration of the alcoholic extract hydroxyl group-OH of element or CMC, band broadening, and move to lower wave number, Show that there is very strong hydrogen bond action in this medicine. 1615.89cm-1The absworption peak at place is alginic acid and carboxymethyl crusta Generate after the carboxyl of element or CMC and Ca interact-the C=O asymmetric stretch of COOCa shakes Moving. 1419cm-1The absorption at place belongs to the symmetrical stretching vibration of C=O, 1031.9cm-1And 1085.7cm-1Come From-the C-C-C-structure.
Medicine of the present invention exists numerous hydroxyls, carboxyl, between them except be bonded to big molecule by calcium ion Outward, they can also form various forms of hydrogen bond associations.
By pharmacodynamics test data in the external body of following medicine of the present invention, can find out that this medicine has lead Significantly scavenging action.
One, the Pharmacodynamics in vitro of medicine of the present invention test
Under the condition that simulates human gastric juice's acidity and ionic strength, investigate this medicine to the suction-operated of lead. Determining instrument: Spectr AA-40 type Atomic Absorption Spectrometer (Varian company)
ICP-900 type ICP (Jarrell-Ash company) Test method: preparation contains the gastric juice that simulates of lead at different concentrations, adds a certain amount of medicine, in 37 ℃ of lower vibrations 5 hours, centrifugal, get supernatant and measure lead, calcium, zinc content. Result of the test:
Table 1, medicine are to the adsorption test result of lead
*Mixed lead: the mixed liquor of plumbi nitras and lead tetraethide
| Plumbous form | Dose (mg/ml) | Concentration (mg/litre) before the absorption | Concentration (mg/litre) after the absorption | Adsorption rate (%) |
| The organic lead of inorganic lead (plumbi nitras) (lead tetraethide) mixed lead* | 5 10 20 30 16 24 | 49.52 49.52 49.52 49.52 0.422 1.375 | 17.48 12.85 2.33 0.4956 129.8 259.6 | 64.7 74.1 95.5 99.0 69.3 81.1 |
Result of the test shows that medicine of the present invention is simulating under the condition of human gastric juice, to inorganic lead (plumbi nitras), Organic lead (lead tetraethide), mixed lead (inorganic, organic lead) all have stronger suction-operated, adsorption rate 64-99%, and with the increase of dose, adsorption rate improves. Shown by calcium zinc measurement result, simulating gastric juice acid Under the condition of degree, the resolution factor of calcium reaches 91-94%, and the resolution factor of zinc reaches 96-98%. Increase calcium and can reduce lead Accumulating and toxicity in tissue; Zinc has important guarantor to the damage of the hippocampus synaptic plasticity that lead causes Protect effect.
Two, pharmacodynamics test in the body
(1) experimental animal: 40 of Wistar rats, male, body weight 150-200g.
(2) test method: divide 3 groups, 10 of control groups (A) are raised with basal feed; The contamination group (B15, Preparation lead concentration 65.9 mg/ml, 1-4 measures 659mg/kg (body weight) gavage once with lead, 5-8 every day in week Measure 329mg/kg (body weight) gavage once with lead every day in week, and feed is basal feed; 15 of administration groups (C), Contaminating mode is identical with the contamination group, and add with 1% cmc soln and be made into 0.12 grams per milliliter (medicine), Every day with dose 15 ml/kg (body weight) gavage once.
(3) eight weeks of test period, each blood sampling of 2,4,8 weeks is once got brain, kidney, liver eight weeks and is measured Pb and contain Amount and organ coefficient.
(4) assay method: sample HNO3、HClO
4Clear up, machine is measured on the constant volume. Instrument model: U.S. State Baird ICP-2070 type plasma emission spectrometer. Standard sample Quality Control: GBW0860 country mark Accurate material, GBW (E) 09006 cow's serum standard specimen.
(5) result of the test:
The variation of table 2, blood lead content (μ mol/L)
| Group | Two weeks | All around | Eight weeks |
| Control group (A) contamination group (B) administration group (C) | 0.7746±0.1758 15.3095±6.9009 9.6993±3.1891 | 1.3241±0.7111 20.2048±7.4842 14.5085±3.7931 | 0.6249±0.4654 6.7524±3.7967 3.3895±2.3663 |
Two all A and B compare P＜0.001 B and C compares P＜0.005;
A and B comparison P＜0.001 B and C compare P＜0.02 all around;
Eight all A and B compare P＜0.001 B and C compares P＜0.01.
Table 3, internal organs lead tolerance (μ g/g)
| Group | Brain | Kidney | Liver |
| Control group (A contamination group (B administration group (C | 4.0274 ±3.5469 47.7348±12.5695 28.6308±9.8454 | 10.0531±7.7186 47.9320±9.6445 18.5882±4.9284 | 4.1067±2.5303 35.4983±6.7761 31.5074±10.8263 |
Brain: A and B compare P＜0.001 B and C compares P＜0.01
Kidney: A and B compare P＜0.001 B and C compares P＜0.001
Liver: A and B be P＜0.001 relatively
(coefficient is: internal organs weight/body weight %) to the impact of organ coefficient for table 4, medicine
* with normal control than P＜0.05 * * and normal control than P＜0.01 # and contamination than P＜0.05
| Internal organs | Normal control | Contamination | Treatment |
| The heart | 0.325±0.026(8) | 0.362±0.031(8) * | 0.351±0.021(7) * |
| Liver | 3.623±0.272(8) | 4.083±0.243(8) ** | 3.766±0.249(7) # |
| Spleen | 0.171±0.030(8) | 0.292±0.060(8) ** | 0.234±0.042(7) **# |
| Kidney | 0.655±0.079(8) | 1.030±0.095(8) ** | 0.957±0.064(7) ** |
Can be found out by the experimental data among the table 1-4:
Shown by test data that 1, each contamination of two weeks is touched type and set up, matched group and contamination group blood lead have utmost point significant difference; Contamination group and administration group blood lead have utmost point significant difference; All around, eight all result of the tests are similar to two weeks.Point out medicine of the present invention that tentative lead poisoning is had tangible eliminating function.
2, eight all internal organs analysis results show, the lead tolerance of brain, kidney, liver, and matched group and contamination group have utmost point significant difference.The lead tolerance of its midbrain, kidney, contamination group and administration group have utmost point significant difference, and lead tolerance contamination group of liver and administration group no significant difference.Brain, injury of kidney that zinc causes lead poisoning have defencive function.
3, eight all blood calcium, blood zinc measurement result show, administration group blood calcium 1248.4 ± 308.2 μ mol/L, and contamination group blood calcium 1159.6 ± 241.8 μ mol/L, the blood calcium of administration group increases by 7.66% than the contamination group; Administration group blood zinc 67.39 ± 11.22 μ mol/L, contamination group blood zinc 60.05 ± 13.08 μ mol/L, the blood zinc of administration group increases by 12.22% than the contamination group.Point out medicine of the present invention to have certain increase blood calcium, the effect of blood zinc, according to reports, calcium, zinc have defencive function to lead poisoning.
4, contamination group and treatment are organized each organ coefficient and all are higher than the normal control group, and contamination group heart P＜0.05, liver P＜0.01, spleen P＜0.01, kidney P＜0.01, brain P＜0.01, administration group heart P＜0.05, spleen P＜0.01, kidney P＜0.01, brain P＜0.01, the liver influence is little.And administration group and contamination group are relatively, and each organ coefficient all is lower than the contamination group, and liver P＜0.05, spleen P＜0.05, have significant difference, and the heart, kidney difference are little.Illustrate that medicine has the effect of protection internal organs, its effect to liver, spleen is more obvious.Plumbous damage to each internal organs is very tangible.
5, animal acute toxicity test: the LD that the mice mouth is raised
50Fail to measure, maximum tolerated dose is the 24.5g/kg body weight, observes 7, and mice body weight, outward appearance, behavioral activity do not occur any unusual, death condition do not occur yet.
Compared with prior art, medicine of the present invention has following characteristics: the plumbous amount of (1) absorption is bigger, and alginic acid contains a large amount of active groups (carboxyl 3meq/g, hydroxyl 3.5-4.0meq/g) can adsorb the lead that enters human body.Test shows under the acidity and ion concentration condition of simulated gastric fluid, and the clearance rate of inorganic lead is reached 65-99%, is 69% to organic lead (lead tetraethyl) clearance rate, and the clearance rate of mixed lead is 80%.Following Comparative Examples shows that also the lead-dispelling effect of medicine of the present invention is stronger.Can also zinc supplement when (2) driving lead.Aspect the treatment lead poisoning, zinc has special effect, and zinc and lead all are divalent ions, and a kind of relation of vying each other is arranged on different physiological levels, and zinc plays an important role in saturnine mechanism.This medicine quantitatively adds zinc, can play a protective role to the damage of lead, and this medicine is again a calcium type preparation (calcium content reaches 8.5%) simultaneously, and zinc, calcium can be resolved in gastric juice, and resolution factor all reaches more than 90%.This shows that but this medicine can drive lead zinc supplement again, calcium, have dual-use function, certain characteristic is relatively arranged with existing Plumbum removing preparation.(3) calcium content of this medicine improves 1-1.5% than the medicine of CN1079387A, can further reduce plumbous accumulating and toxicity in the tissue.(4) this medicine belongs to marine organism extract, and human body is had no side effect and taking convenience, both can be used for the treatment of chronic lead poisoning, also can be used for the prevention of children ' s lead poisoning.
This shows that this medicine can be prevented and treated lead poisoning effectively, implementing the present invention will play a good protection to children ' s intelligence development.The plumbous object of having been classified as keypoint control as neurotoxic substance by country.
In addition, medicine of the present invention also can be used for preventing and treating the murder by poisoning of hydrargyrum, cadmium etc.
The following examples are to further specify of the present invention, and protection scope of the present invention is not limited by following embodiment to be as the criterion.
Example 1:
900 milliliters of the solution of sodium alginate of concentration 3% (weight: below be concentration expressed in percentage by weight), 300 milliliters of the carboxymethyl chitosan sodium salt solutions of adding concentration 1.5%, stir, add excessive 0.5% calcium lactate solution, carry out gelling reaction, treat that gel is all separated out after, take out gel, washing, dry under 60 ℃, cross 80 mesh sieves, (its weight is about 85% of jello with powder, be soaked in the zinc nitrate solution that 1140 ml concns are 200 mg/litre down together), stirred 2 hours, centrifuge dehydration, 60 ℃ are dry down, sneak into excipient, make tablet.
Example 2:
450 milliliters of the solution of sodium alginate of concentration 4%, 90 milliliters of the carboxymethyl chitin sodium salt solutions of adding 4% stir, add excessive 5% calcium chloride solution, fully stir, carry out gelling reaction, treat that gel separates out fully, take out gel, washing, 70 ℃ dry down, pulverizes, and powder is soaked in the solution of zinc sulfate that 280 ml concns are 500 mg/litre stirred 1 hour, centrifuge dehydration, 70 ℃ dry down, adds lactose, sucrose or Mel again, can be made into preparations such as pill or serosity.
Example 3:
9000 milliliters of the solution of sodium alginate of concentration 2%, 200 milliliters of the carboxymethyl chitosan sodium salt solutions of adding concentration 10%, stir, adding excess amount of Ca concentration is 1.7% vinegar system Concha Ostreae (calcined) solution, carry out gelling reaction, gel occurs, it is clear that reactant liquor becomes, and takes out gel, washing, 80 mesh sieves were pulverized in 80 ℃ of oven dry down, powder is soaked in the zinc acetate solution that 1700 ml concns are 850 mg/litre stirred 3 hours, centrifuge dehydration, 80 ℃ of oven dry down are crushed to 100 orders, make powder or capsule.
Example 4:
4000 milliliters of the na alginate solns of concentration 1% add 2000 milliliters of concentration 2% carboxymethyl chitin sodium salt solutions, fully stirring and evenly mixing, add excessive 2% calcium acetate solution, carry out gelling reaction, generate gel precipitate, the washing gel, natural drying is crushed to 60 orders, powder is soaked in the liquor zinci chloridi that 1450 ml concns are 400 mg/litre, stirred centrifuge dehydration 1 hour, natural drying, be crushed to 80 orders, add solution such as Radix Acaciae senegalis, pectin, make oral liquid.
Example 5:
2000 milliliters of the solution of sodium alginate of concentration 5%, 200 milliliters of the carboxymethyl chitin sodium solutions of adding concentration 5% fully stir evenly, add excessive 30% calcium acetate solution, carry out gelling reaction, generate gel, through washing, 40 ℃ dry down, pulverizes and make powder, powder is soaked in the zinc acetate solution that 1300 ml concns are 600 mg/litre, stirred 1 hour, centrifuge dehydration, 40 ℃ are dry down, add an amount of disintegrating agent, make tablet.
Example 6:
2000 milliliters of the na alginate solns of concentration 6%, 1500 milliliters of the carboxymethyl chitosan sodium salt solutions of adding concentration 2% stir evenly, add excessive 10% calcium acetate solution, carry out gelling reaction, generate gel, through washing, centrifuge dehydration, dry down at 50 ℃, be crushed to 100 orders, be soaked in the zinc nitrate solution that 1550 ml concns are 700 mg/litre and stirred 2 hours, centrifuge dehydration, dry down in 70 ℃, make powder, make an addition to and make lead excluding health care food in the food.
Example 7:
2000 milliliters of the na alginate solns of concentration 2.5%, 1000 milliliters of the carboxymethyl chitin sodium salt solutions of adding concentration 3%, stirring and evenly mixing, add excessive 5% calcium nitrate solution, carry out gelling reaction, generate gel, through washing, centrifuge dehydration, dry under 70 ℃, be crushed to 70 orders, be soaked in the solution of zinc sulfate that 960 ml concns are 600 mg/litre and stirred 1 hour, centrifuge dehydration, dry under 100 ℃, make medicine.
Example 8:
1000 milliliters of the na alginate solns of concentration 5%, 500 milliliters of the carboxymethyl chitin sodium salt solutions of adding concentration 8%, fully mixing, add excessive 20% calcium acetate solution, carry out gelling reaction, generate gel, through washing, centrifuge dehydration, dry under 70 ℃, be crushed to 100 orders, be soaked in the zinc acetate solution that 870 ml concns are 750 mg/litre and stirred 2 hours, centrifuge dehydration, dry under 90 ℃, make powder.
Comparative Examples:
Contain at two and to add the medicine of example 5 among the 1gCN1079387A and the medicine of example of the present invention 3 in 50 ml solns that lead concentration is the 95-105 mg/litre respectively, experimental technique: isothermal vibration 3 hours, filter, get filtrate and measure plumbous residual quantity, calculate clearance lead.Result of the test shows, the clearance 78.57% of the former lead, and the clearance 96.21% of latter's lead shows that medicine of the present invention drives plumbous rate than CN1079387A patent drug and improves 17.64%.
Claims (10)
1, a kind ofly treat and prevent saturnine medicine, it is characterized in that described medicine comprises:
A, concentration expressed in percentage by weight is the solution of sodium alginate of 0.5-6%;
B, concentration expressed in percentage by weight is the carboxymethyl chitin of 1-10% or the sodium salt solution of carboxymethyl chitosan;
C, concentration expressed in percentage by weight is the solubility calcium saline solution of 0.5-30%;
D, concentration is the soluble Zn saline solution of 200-850 mg/litre;
This medicine can be made as follows:
(1) A component and B component are pressed (10～1): 1 weight ratio fully stirs, mix homogeneously;
(2) in A, B component mixed glue solution, add the C component, in solution, carry out gelling reaction, become clear solution up to reactant liquor, till gel is separated out;
(3) take out gel, through washing, drying is made powder;
(4) will be 1 with the D components by weight: the powder that the above-mentioned steps of (1～50) (3) makes be soaked in the D component, and jolting 0.5-3 hour, centrifuge dehydration, 0-100 ℃ is dry down, pulverizes and makes medicine of the present invention.
2, treatment as claimed in claim 1 and prevent saturnine medicine is characterized in that: the alginic acid in the described A component is the two a block copolymer of D-mannuronic acid and L-guluronic acid, and the ratio of the two is (1～2): 1.
3, treatment as claimed in claim 1 and prevent saturnine medicine is characterized in that: the alginic acid in the described A component is extracted by Sargassum, Thallus Laminariae (Thallus Eckloniae).
4, treatment as claimed in claim 1 and prevent saturnine medicine is characterized in that: described B component gets by the shell-fish biological extraction and through carboxy methylation.
5, treatment as claimed in claim 1 and prevent saturnine medicine is characterized in that: described C component is selected from a kind of in calcium acetate, calcium chloride, calcium lactate, the vinegar system Concha Ostreae (calcined) solution.
6, treatment as claimed in claim 1 and prevent saturnine medicine is characterized in that: described D component soluble zinc salt is selected from a kind of in zinc chloride, zinc nitrate, zinc acetate or the zinc sulfate, and it contains zinc concentration is the 400-850 mg/litre.
7, treatment as claimed in claim 1 and prevent saturnine medicine, it is characterized in that: in concentration expressed in percentage by weight, the A component concentrations is 1-3%; The B component concentrations is 2-5%; The C component concentrations is 0.5-10%.
8, as the described treatment of one of claim 1-7 and the preparation method of preventing saturnine medicine, may further comprise the steps:
(1) A component and B component are pressed (10～1): 1 weight ratio fully stirs, mix homogeneously;
(2) add the C component slowly in A, B component mixed glue solution, carry out gelling reaction in solution, become clear solution up to glue, pH reaches 7, till gel is separated out;
(3) take out gel, through the washing desalination, dehydration, drying is made Powdered middle product;
(4) will be 1 with the D components by weight: the powder that the above-mentioned steps of (1～50) (3) makes be soaked in the D component, and jolting 0.5-3 hour, centrifuge dehydration, drying is made medicine of the present invention.
9, the treatment as claimed in claim 8 and the preparation method of preventing saturnine medicine, it is characterized in that: the baking temperature in described step (3) and the step (4) is 0-100 ℃.
10, as the described treatment of one of claim 1～7 with prevent saturnine medicine, it is characterized in that: except that A, B, C, D four components, add the excipient that accounts for gross weight 0～5% again, described excipient is selected from one or more of sodium carboxymethyl cellulose, starch, pectin, Radix Acaciae senegalis, lactose, sucrose, stearic acid, hard magnesium or mannitol etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00106079A CN1085080C (en) | 2000-04-20 | 2000-04-20 | Medicine for treating and preventing saturnism and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00106079A CN1085080C (en) | 2000-04-20 | 2000-04-20 | Medicine for treating and preventing saturnism and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1271580A CN1271580A (en) | 2000-11-01 |
| CN1085080C true CN1085080C (en) | 2002-05-22 |
Family
ID=4578124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00106079A Expired - Fee Related CN1085080C (en) | 2000-04-20 | 2000-04-20 | Medicine for treating and preventing saturnism and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1085080C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103349731B (en) * | 2013-05-31 | 2015-03-04 | 吴艾潼 | Traditional Chinese medicine for treating dysspermia male infertility |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD1964C2 (en) * | 2001-09-19 | 2003-01-31 | Константин МАТКОВСКИ | Antidote for neutralization of cyanides |
| MD2067C2 (en) * | 2002-03-22 | 2003-09-30 | Константин МАТКОВСКИ | Antidote for cyanide neutralization |
| CN102335208A (en) * | 2011-08-25 | 2012-02-01 | 中国林业科学研究院林产化学工业研究所 | Application of pine needle extract to preparation of medicine or health care product having function of promoting lead discharge |
| CN103393731B (en) * | 2013-07-24 | 2016-01-20 | 绍兴文理学院 | One drives mercurial |
| CN103539868B (en) * | 2013-11-01 | 2016-05-04 | 上海春露生物化学有限公司 | A kind of method of preparing CMC |
| CN108812696A (en) * | 2018-05-16 | 2018-11-16 | 湖南农业大学 | A kind of corn drop cadmium agent |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1037660C (en) * | 1993-04-24 | 1998-03-11 | 中国科学院国家计划委员会地理研究所 | Alginic acid-hydroxy polybasic benzene carboxylic acid calcium type medicament for curing uremia and heavy metal poisoning and its preparation method |
-
2000
- 2000-04-20 CN CN00106079A patent/CN1085080C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1037660C (en) * | 1993-04-24 | 1998-03-11 | 中国科学院国家计划委员会地理研究所 | Alginic acid-hydroxy polybasic benzene carboxylic acid calcium type medicament for curing uremia and heavy metal poisoning and its preparation method |
Non-Patent Citations (1)
| Title |
|---|
| MEDLINE EXPRESS:1987290638 1987.01.01 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103349731B (en) * | 2013-05-31 | 2015-03-04 | 吴艾潼 | Traditional Chinese medicine for treating dysspermia male infertility |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1271580A (en) | 2000-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI690274B (en) | Metal ion-functional fiber component complex compositions, preparation and uses thereof | |
| CN1108572A (en) | Antiulcer agent and adhesion inhibitor for helicobacter pyroli | |
| CN1875996A (en) | A composition having anti-oxygenation function | |
| CN1606472A (en) | Adsorbent for phosphoric acid | |
| KR20160121534A (en) | Composition comprising okra for use in reducing dietary fat absorption | |
| CN1085080C (en) | Medicine for treating and preventing saturnism and its preparing process | |
| CN1201786C (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
| CN1384750A (en) | Plant extract mixtures and their uses | |
| CN102150854B (en) | Health food with auxiliary protection function to chemical liver injury | |
| TWI589232B (en) | Iron-fiber composition, preparation and uses thereof | |
| CN1799411A (en) | Diet fiber composition with intestine-nourishing constipation-releving functions and its production method | |
| CN1287687C (en) | Lead-removing health care food and preparation method thereof | |
| CN1799409A (en) | Diet fiber composition with fat-reducing face-beautifying functions and its production method | |
| CN1202067C (en) | Medicinal grade ferrum citricum iron-59 citrate and its preparation method | |
| CN1227267C (en) | Spiruline polyose, its extraction process and it medical application in increasing white cells and treating cancer | |
| CN1915324A (en) | Preparation of reenforcing spleen for wean, and preparation method | |
| WO2021174801A1 (en) | Method for preparing antrodia cinnamomea water-insoluble dietary fibers | |
| CN1646100A (en) | Dispersed solid-containing complex carbohydrate | |
| JP3719478B2 (en) | Diet food | |
| CN111437313A (en) | Traditional Chinese medicine pill for relaxing bowel and preparation method thereof | |
| CN101040866A (en) | Application of flyblow chitosan in the preparation of products for regulating blood lipid | |
| Rasmussen et al. | Chitin and chitosan | |
| Yong et al. | Chitosan for Body Weight Management | |
| CN109549967A (en) | A kind of sophora alapecuroides slow-releasing granules and preparation method thereof | |
| JP2004051615A (en) | Bile acids adsorbent using chitosan-orotic acid salt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20020522 |